Literature DB >> 1589406

Lyophilized formulations of recombinant tumor necrosis factor.

M S Hora1, R K Rana, F W Smith.   

Abstract

Recombinant tumor necrosis factor-alpha (TNF), an investigational biological response modifier, is a protein and is susceptible to particulate generation during handling in dilute aqueous solutions. TNF is prone to formation of nonreducible dimers and oligomers during formulation, lyophilization, and storage. The effect of various parameters, such as the pH, protein concentration, and nature of excipients present during lyophilization, on the formation of nonreducible dimers and oligomers was investigated. The results of these studies indicate that these parameters can significantly alter the rate of this reaction. Inclusion of an amorphous buffer and an appropriate amount of a crystallizing sugar (mannitol) combined with a suitable quantity of an amorphous protectant (dextran, sucrose, trehalose, or 2-hydroxypropyl-beta-cyclodextrin) was shown to reduce the formation of these dimeric and oligomeric species during lyophilization. Representative lyophilized formulations of TNF based on selected amorphous excipients were found to be fully bioactive and stable over 9 months.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1589406     DOI: 10.1023/a:1018919508463

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  12 in total

1.  Tumour necrosis factor as immunomodulator and mediator of monocyte cytotoxicity induced by itself, gamma-interferon and interleukin-1.

Authors:  R Philip; L B Epstein
Journal:  Nature       Date:  1986 Sep 4-10       Impact factor: 49.962

Review 2.  Tumor necrosis factor: immunologic, antitumor, metabolic, and cardiovascular activities.

Authors:  C Grunfeld; M A Palladino
Journal:  Adv Intern Med       Date:  1990

3.  The active form of tumor necrosis factor is a trimer.

Authors:  R A Smith; C Baglioni
Journal:  J Biol Chem       Date:  1987-05-25       Impact factor: 5.157

4.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

5.  Biological effects of recombinant human tumor necrosis factor and its novel muteins on tumor and normal cell lines.

Authors:  A A Creasey; L V Doyle; M T Reynolds; T Jung; L S Lin; C R Vitt
Journal:  Cancer Res       Date:  1987-01-01       Impact factor: 12.701

6.  Molecular cloning of the complementary DNA for human tumor necrosis factor.

Authors:  A M Wang; A A Creasey; M B Ladner; L S Lin; J Strickler; J N Van Arsdell; R Yamamoto; D F Mark
Journal:  Science       Date:  1985-04-12       Impact factor: 47.728

7.  Tumour necrosis factor is a compact trimer.

Authors:  P Wingfield; R H Pain; S Craig
Journal:  FEBS Lett       Date:  1987-01-26       Impact factor: 4.124

8.  Human tumor necrosis factor. Production, purification, and characterization.

Authors:  B B Aggarwal; W J Kohr; P E Hass; B Moffat; S A Spencer; W J Henzel; T S Bringman; G E Nedwin; D V Goeddel; R N Harkins
Journal:  J Biol Chem       Date:  1985-02-25       Impact factor: 5.157

9.  An improved colorimetric assay for interleukin 2.

Authors:  H Tada; O Shiho; K Kuroshima; M Koyama; K Tsukamoto
Journal:  J Immunol Methods       Date:  1986-11-06       Impact factor: 2.303

10.  Analysis of the molecular organization of recombinant human tumor necrosis factor (rTNF) in solution using ethylene glycolbis(succinimidylsuccinate) as the cross-linking reagent.

Authors:  K S Lam; P Scuderi; S E Salmon
Journal:  J Biol Response Mod       Date:  1988-06
View more
  8 in total

Review 1.  Past, present, and future technologies for oral delivery of therapeutic proteins.

Authors:  Rajesh Singh; Shailesh Singh; James W Lillard
Journal:  J Pharm Sci       Date:  2008-07       Impact factor: 3.534

2.  Effect of Formulation and Process Parameters on the Disproportionation of Indomethacin Sodium in Buffered Lyophilized Formulations.

Authors:  Sampada Koranne; Seema Thakral; Raj Suryanarayanan
Journal:  Pharm Res       Date:  2018-01-05       Impact factor: 4.200

3.  A central composite design to investigate the thermal stabilization of lysozyme.

Authors:  S Branchu; R T Forbes; P York; H Nyqvist
Journal:  Pharm Res       Date:  1999-05       Impact factor: 4.200

4.  Decreased protein-stabilizing effects of cryoprotectants due to crystallization.

Authors:  K Izutsu; S Yoshioka; T Terao
Journal:  Pharm Res       Date:  1993-08       Impact factor: 4.200

5.  Aggregates formed during storage of beta-galactosidase in solution and in the freeze-dried state.

Authors:  S Yoshioka; Y Aso; K Izutsu; T Terao
Journal:  Pharm Res       Date:  1993-05       Impact factor: 4.200

6.  Increased stabilizing effects of amphiphilic excipients on freeze-drying of lactate dehydrogenase (LDH) by dispersion into sugar matrices.

Authors:  K Izutsu; S Yoshioka; S Kojima
Journal:  Pharm Res       Date:  1995-06       Impact factor: 4.200

7.  Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody (mAb) by Neutralizing TNF Using an In Vitro Bioanalytical Method.

Authors:  Lilia Tierrablanca-Sánchez; Víctor Pérez Medina Martínez; Nancy D Ramírez Ibañez; Néstor O Pérez Ramírez; Francisco Luis Flores Ortiz; Emilio Medina-Rivero
Journal:  J Vis Exp       Date:  2017-09-16       Impact factor: 1.355

8.  Effects of insulin concentration and self-association on the partitioning of its A-21 cyclic anhydride intermediate to desamido insulin and covalent dimer.

Authors:  R T Darrington; B D Anderson
Journal:  Pharm Res       Date:  1995-07       Impact factor: 4.200

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.